Director Janet Dillione sells 10,000 CorMedix (CRMD) shares at $6.88

Rhea-AI Filing Summary

CorMedix Inc. director Janet Dillione reported a sale of company stock. On January 21, 2026, she sold 10,000 shares of CorMedix common stock at a weighted average price of $6.88 per share, in multiple trades executed between $6.85 and $6.90 per share. After this transaction, she beneficially owned 38,473 shares of CorMedix common stock directly.

The filing notes that the reported price is an average across several individual trades, and the director has agreed to provide detailed trade and pricing information to regulators, the company, or any security holder who requests it.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dillione Janet

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		S		10,000	D	$6.88(1)	38,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $6.85 to $6.90, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix Inc. (CRMD) disclose?

CorMedix Inc. disclosed that director Janet Dillione sold 10,000 shares of the company’s common stock in an open-market transaction.

At what price did Janet Dillione sell CorMedix (CRMD) shares?

The reported weighted average sale price was $6.88 per share, with individual trades executed at prices ranging from $6.85 to $6.90 per share.

How many CorMedix (CRMD) shares does the director own after the sale?

Following the reported sale, director Janet Dillione beneficially owned 38,473 shares of CorMedix common stock directly.

What does the Form 4 for CorMedix (CRMD) say about how the trades were executed?

The Form 4 states that the sale was executed in multiple trades between $6.85 and $6.90 per share, and the $6.88 price reported is a weighted average.

Can investors get more detailed pricing data for the CorMedix (CRMD) insider sale?

Yes. The director undertook to provide the SEC staff, the company, or any security holder with full details on the number of shares and exact prices upon request.

What role does Janet Dillione hold at CorMedix Inc. (CRMD)?

According to the filing, Janet Dillione is a director of CorMedix Inc.